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Background: The aim of this study is to compare the efficacy of intensification of insulin treatment with insulin
glargine and biphasic human insulin in patients with type 2 diabetes on concomitant therapy with oral antidiabetic
drugs (OAD) in daily clinical practice.
Methods: A retrospective multicentre parallel two-arm study included 301 patients with type 2 diabetes already on
treatment with biphasic human insulin twice daily (bd) in combination with OAD. Data were collected
retrospectively from 142 patients who had been switched from biphasic human insulin to insulin glargine in a
period of 6–12 months prior to their inclusion (active group) and compared to data collected retrospectively from
159 patients who continued treatment with biphasic human insulin bd for the same time period (control group). Our
primary objective was to examine the efficacy of the two treatments, assessed as change in HbA1c. Secondary objectives
were to examine for changes in fasting blood glucose (FBG), body weight, treatment with OAD or fast-acting insulin and
safety, by assessing the frequency and severity of hypoglycaemic episodes.
Results: At the end of the study there was a significant reduction in HbA1c in both arms. The least squares (LS) mean
[(95% confidence intervals (CI)] reduction in HbA1c was −1.13 (−0.96 to −1.30)% in the active and −0.59 (−0.41to −0.77)%
in the control group [LS mean treatment difference 0.53 (0.31-0.76)%, p < 0.001]. Similarly, fasting blood glucose declined
significantly in both arms. The LS mean decline in FBG was −47.02 (−37.89 to −56.14) mg/dl in the active and −19.73
(−11.57 to −27.89) mg/dl in the control group [LS mean treatment difference 27.85 (15.74-39.95) mg/dl, p < 0.001]. No
significant difference in hypoglycaemic episodes and in body weight was found. In the active group, more patients
received rapid-acting pre-meal insulin and used insulin secretagogues drugs.
Conclusions: Glargine alone or in combination with fast acting insulin is more effective in reducing glycaemia than
biphasic human insulin alone or in combination with fast acting insulin in patients with type 2 diabetes without increase
in hypoglycaemic episodes or body weight.
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Male 73 (45.9) 60 (42.3) 0.523
Female 86 (54.1) 82 (57.8)
Age (years) 66.7 ± 9.6 63.2 ± 10.1 0.002
ΒΜΙ (kg/m2) 31.1 ± 8.6 29.3 ± 5.4 0.029
Height (cm) 162.8 ± 12.5 164.6 ± 8.4 0.146
Weight (kg) 80.8 ± 12.7 79.3 ± 14.2 0.331
Years diagnosed 16.0 ± 8.6 13.5 ± 7.8 0.011
Duration of monitoring
period (months)
9.3 ± 1.9 9.1 ± 2.0 0.291
HbA1c (%) 8.18 ± 1.33 8.53 ± 1.29 0.019
FBG (mg/dl) 168 ± 47.2 182.6 ± 57.1 0.025
Data are mean ± SD or n (%).
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Insulin administration in patients with type 2 diabetes
mellitus (T2DM) has proved to be the most effective treat-
ment modality, which should be initiated early in the
course of the disease in case lifestyle modification and/or
metformin administration fail to achieve recommended
glycaemic standards [1,2]. Insulin can be administered in
addition to oral hypoglycaemic therapy and in different
therapeutic schemes which can be prospectively modified
based on close glycosylated haemoglobin A1c (HbA1c)
and blood glucose (BG) monitoring [3].
The primary objective of the present retrospective
study (LANTus utilisation in real life versus PREmix In-
sulin, PRELANTI) was to assess the efficacy of intensifi-
cation of treatment, by measuring the change in HbA1c,
of two main insulin treatment schemes: (a) glargine once
daily in the evening and (b) biphasic human insulin
twice daily (bd) in patients with T2DM on concomitant
therapy with oral antidiabetic drugs (OAD). Secondary
objectives were to examine for changes in fasting BG,
body weight, treatment with OAD or insulin and safety,
by assessing the frequency and severity of hypoglycaemic
episodes. In both treatment groups, fast acting insulin
was added if needed.
Research design and methods
A retrospective parallel two-arm study was designed to
include 332 patients with T2DM, equally distributed in
two treatment groups. Taking into consideration that
difference in HbA1c change is 0.34% in favour of insulin
glargine versus premixed insulins in similar comparative
studies between insulin treatment strategies [4], a sam-
ple size of 332 participants were required to be enrolled
in the study with an alpha risk (2-sided test) of 5% and
80% power, as well as with a standard deviation of 1.1%.
Finally, 301 patients, already on treatment with biphasic
human insulin bd in combination with OADs, were
recruited in 10 centers (including both National Health
Services and university hospitals and private practice
doctors) throughout Greece. The study was approved by
hospitals research ethics committees and by National
Organization for Medicines.
Patients’ selection by investigators and inclusion in the
study was taking place consecutively, starting from most
recent patient’s data (from each patient’s last visit) and
going backwards in time. In each centre, data were col-
lected retrospectively from 142 consecutive patients with
T2DM, who had been switched from human biphasic in-
sulin to insulin glargine once daily in a period of 6 –
12 months prior to their inclusion in the study (active
group), and compared to data collected retrospectively
from 159 consecutive patients who continued treatment
with biphasic human insulin bd for the same time period
of 6 – 12 months prior to their inclusion in the study(control group). Fast acting insulin was added in both
groups if considered necessary, depending on the values
of HbA1c and BG at the attending physician’s discretion.
OADs were also added or withdrawn on the basis of the
attending physician’s global assessment of the efficacy of
treatment schemes and the changes were reported on
the patients’ case records. Baseline characteristics of
study population are given in Table 1.
Data were collected from the medical records for all
studied variables and for total insulin dose administered,
number of injections and changes in body weight during
the monitoring period. Regarding hypoglycaemia, we
reported the number and the severity of hypoglycaemic
episodes as well nocturnal hypoglycaemia. Severe
hypoglycaemia was defined as any hypoglycaemic epi-
sode that the patient was unable to self-treat requiring
the assistance of another person to deal with it [5]. All
the other cases of hypoglycaemia (documented symp-
tomatic hypoglycaemia, asymptomatic hypoglycaemia,
probable symptomatic hypoglycaemia and relative
hypoglycaemia) were considered as mild/moderate
hypoglycaemia [5].
Statistical analysis
Data were analyzed separately in each treatment group
(control/active group). Continuous variables were presented
by measures of central tendency and dispersion, whereas
categorical variables by frequency distribution tables. The
comparability of the two treatment groups regarding base-
line data was assessed by means of t-student distribution
tests for continuous variables and via chi-square Pearson’s
tests of independence or Fisher’s exact tests for categorical
variables, respectively. The least squares (LS) mean differ-
ences and two-sided 95% confidence intervals (CI) were esti-
mated for the comparisons of the changes in HbA1c, FBG
and body weight between the active and the control group.
Tentolouris et al. Diabetology & Metabolic Syndrome 2013, 5:43 Page 3 of 8
http://www.dmsjournal.com/content/5/1/43The comparability of treatment groups regarding the num-
ber of hypoglycaemic incidences was assessed by means of
Wilcoxon rank-sum test. The evaluation of the change in
the proportion of patients receiving orally administered
antidiabetic treatment from the start until the end of the
monitoring period was performed by means of McNemar
test. The statistically significant variables were identified
according to the analysis of covariance (ANCOVA) method-
ology. The statistical significance of body weight changes
in each treatment group was evaluated by one-way ana-
lysis of variance (ANOVA) tests. The hypothesis of equal
hypoglycaemic incidence rates between the two treatment
groups was assessed by the estimation of relative risk (RR)
and 95% confidence intervals (CI), while the hypothesis of
equal rapid acting insulin intake was assessed by the esti-
mation of odds ratio (OR, 95% CI). All statistical tests
were two-tailed and the significance level was set to 5%.Results
Baseline characteristics
At baseline, the patients of the active group were youn-
ger compared to the control group and this difference
reached statistical significance. Furthermore active group
had a significantly lower body mass index and shorter
known duration of diabetes mellitus. In addition, active
group had a significantly higher HbA1c and fasting BG
when compared to control group (Table 1).
Equal number of participants had been treated with met-
formin, sulfonylurea, meglitinides and alpha-glucosidase
inhibitors in the control and the active group at baseline.
However, more patients received thiazolidinediones in the
active group (Table 2).Efficacy of treatment
During the monitoring period there was a significant re-
duction in HbA1c levels in both treatment groups. The LS
mean (95% CI) reduction of HbA1c value was −1.13 (−0.96
to −1.30)%] in the active and-0.59 (−0.41 to −0.77)%] in the
control group. The LS mean (95% CI) difference of HbA1c
between the active and the control group was 0.53 (0.31-
0.76)% (p < 0.001) (Table 3, Figure 1A). At the end of the
monitoring period a total of 29.6% of patients in the
active and 23.2% of patients in the control group
reached HbA1c < 7% (χ2 = 1.54, p = 0.21) and 6.3% of
patients in the active and 9.4% of patients in the con-
trol group reached HbA1c < 6.5% (χ2 = 0.64, p = 0.42).
Fasting BG declined significantly in both treatment
groups during the monitoring period. The LS mean de-
cline in FBG was −47.02 (−37.89 to −56.14) mg/dl in the
active and −19.73 (−11.57 to −27.89) mg/dl in the con-
trol group The LS mean (95% CI) difference of fasting
BG between the active and the control group was 27.85
(15.74-39.95) mg/dl (p < 0.001) (Table 3, Figure 1B).Hypoglycaemic episodes
The monthly number of mild/moderate hypoglycaemic
episodes, the nocturnal episodes, and the serious
hypoglycaemic episodes did not differ significantly be-
tween the treatment groups during the monitoring
period (Tables 4 and 5).Changes in body weight
In the control group, body weight at baseline was 80.8 ±
12.7 kg and at the end of the monitoring period 81.6 ±
12.9 kg (p = 0.331); the LS mean (95% CI)% change in
body weight was 0.734 (0.139, 1.330) (p = 0.012). In the
active group, body weight was 79.3 ± 14.2 kg at baseline
and 79.4 ± 14.4 kg at the end of the monitoring period
(p = 0.170).; the LS mean (95% CI)% change in body
weight was −0.121 (−0.754, 0.511) kg. The LS mean
(95% CI)% difference in body weight change between the
active and the control group was 0.856 (−0.013, 1.725)
kg (p = 0.054).Daily insulin use
At baseline, the daily dose of biphasic human insulin
was not different between the active and the control
group (p = 0.18). At the end of the monitoring period, in
the control treatment group there was an increase in the
total daily dose of insulin in comparison with the base-
line (from 47.84.0 U/day to 50.89 U/day, p < 0.001). At
the end of the monitoring period, in the active treatment
group, there was a reduction in the total daily dose of in-
sulin (from 44.75 U/day to 42.97 U/day, p < 0.001). Simi-
lar changes were found in total daily insulin dose
expressed in U/kg/day (Table 2).
At the end of the monitoring period, a total of 13 pa-
tients in the control group (8.2%) and 99 patients in the
active group (69.7%) received pre-meal rapid acting insu-
lin [OR: 0.04; 95% CI (0.02, 0.08), p < 0.001]. The per-
centage of the patients who received rapid-acting insulin
in the active group was by 58.7% (95% CI: 49.2, 68.2;
p < 0.001) higher than that in the control group. The
mean value of the rapid-acting insulin units received
by the patients in the active group was by 13.7U/day
(95% CI: 3.6, 23.9; p < 0.001) greater than that re-
ceived by patients of the control group. The number
of insulin injections and the dose of the rapid-acting
insulin at the end of the monitoring period in the two
treatment groups is shown in Table 6.
At the end of the study, a total of 31.7% of the patients
in the active group were managed only with basal insulin
glargine, while the rest of the patients needed the
addition of prandial insulin (one dose: 14.1%; two doses:
19.0%; three: doses: 34.5%; and four doses: 0.7%). A total
of 10.1% of the patients in the control group were man-
aged with one injection of biphasic insulin, 53.5% with 2
Table 2 Orally administered anti-diabetic drugs (OAD) and insulin at baseline and the end of the monitoring period
Control group Active group p-value
Start of the monitoring period n (%) or mean value ± SD
Metformin 71 (44.7) 64 (45.1) 0.942
Sulfonylureas 15 (9.4) 14 (9.9) 0.901
Meglitinides (repaglinide/nateglinide) 0 (0.0) 0 (0.0) -
Thiazolidinedions 3 (1.9) 10 (7.0) 0.028
Alpha-glucosidase inhibitor 2 (1.3) 1 (0.7) 1.0
Other* 1 (0.6) 0 (0.0) 1.0
Biphasic human insulin (U/day) 47.84 ± 20.05 44.75 ± 19.85 0.18
Biphasic human insulin (U/kg/day) 0.61 ± 0.27 0.56 ± 0.25 0.13
End of the monitoring period n (%)
Metformin 63(39.6) 62 (43.7) 0.478
Sulfonylurea 2 (1.3) 18 (12.7) <0.001
Meglitinides (repaglinide/nateglinide) 0 (0.0) 6 (4.2) 0.009
Thiazolidinedions 1 (0.6) 7 (4.9) 0.021
Alpha-glucosidase inhibitor 1 (0.6) 1 (0.7) 1.0
Other* 1 (0.6) 2 (1.4) 0.604
Total insulin (glargine or biphasic plus
prandial) dose (U/day)
50.89 ± 21.56 42.97 ± 21.53 <0.001
Total insulin (glargine or biphasic plus
prandial) dose (U/kg/day)
0.65 ± 0.28 0.53 ± 0.26 <0.001
Change [%, 95% confidence intervals, (CI)] in the OAD and daily insulin dose between baseline and the end of the monitoring period
%, 95% CI %, 95% CI
Metformin −5.0 (−9.5, -0.4) −1.4 (−6.6, 3.8)
p-value (baseline vs end) 0.033 0.593
Sulfonylureas −8.1 (−12.9, 0.4) 2.8 (−3.9, 3.8)
p-value (baseline vs end) 0.001 0.393
Meglitinides (repaglinide/nateglinide) 0.0 4.2 (0.8, 7.6)
p-value (baseline vs end) - 0.014
Thiazolinidiones −1.3 (−3.0, 0.5) −2.1 (−5.2, 1.0)
p-value (baseline vs end) 0.157 0.180
Alpha-glusidase inhibitor 0.0 0.0
p-value (baseline vs end) 0.317 -
Other* 0.0 (−1.7, 1.7) 1.4 (−0.5, 3.4)
p-value (baseline vs end) 1.0 0.157
Total insulin (glargine or biphasic plus prandial) dose (U/day) 3.49 (2.16, 4.82) −1.78 (−5.25, -1.69)
p-value (baseline vs end) <0.001 0.01
Total insulin (glargine or biphasic plus prandial) dose (U/kg/day) 0.04 (0.02, 0.06) −0.02 (−0.07, -0.01)
p-value (baseline vs end) <0.001 0.007
*Other includes dipeptidyl-peptidase 4 inhibitors or glucagon-like peptide 1 mimetics.
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tions daily (Table 6).
Concomitant treatment with OAD
Metformin was discontinued in 5% (p = 0.003) of the pa-
tients in the control and in 1.4% of the patients in theactive group (p = 0.593) by the end of the study period.
In addition, the use of sulfonylureas was reduced by
8.1% (p = 0.001) in the control and was increased by
2.8% (p = 0.393) in the active group. A significant also
increase (by 4.2%, p = 0.014) was found in the use of
meglitinides in the active group by the end of the
Table 3 HbA1c and fasting blood glucose (FBG) levels per








Prior treatment 8.18 ± 1.33 8.53 ± 1.29
After treatment 7.58 ± 1.06 7.39 ± 0.81
p-value (baseline vs end)‡ <0.001 <0.001
LS mean difference (95% CI) 0.53 (0.31-0.76) <0.001
FBG (mg/dl)
Prior treatment 168.9 ± 47.2 182.6 ± 57.1
After treatment 148.5 ± 42.7 135.6 ± 34.5
p-value(baseline vs end) ‡ <0.001 <0.001
LS mean difference (95% CI) 27.85 (15.74-39.95) <0.001
†Statistically significant difference between the control and the active group.




Figure 1 Changes in HBA1c and fasting blood glucose levels.
A The reduction in HbA1c levels in the control (grey bars) and the
active group (black bar) after 6–12 months of follow up. Least
squares mean difference between the active and the control group
0.53 (0.31-0.76)%, p < 0.001. B The reduction in fasting blood
glucose levels (FBG) in the control (grey bars) and the active group
(black bar) after 6–12 months of follow up. Least squares mean
difference between the active and the control group 27.85 (15.74-
39.95) mg/dl, p < 0.001.
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use of other OAD was noticed during the follow up
period (Table 2).
Discussion
The importance of good glycaemic control constitutes
the cornerstone of every therapeutic modality in patients
with diabetes. Prospective randomised studies have
clearly shown that effective diabetes control, as judged
by HbA1c, is associated with lower incidence of chronic
complications, especially microangiopathy, both in pa-
tients with type 1 and type 2 diabetes [6,7]. The same
applies to satisfactory targeting of postprandial hypergly-
caemia that constitutes an independent risk factor for
the development of diabetic complications [8].
The therapeutic goals in terms of HbA1c level s and of
fasting and post prandial blood glucose values have been
based on large epidemiological studies associating glucose
control with the incidence of diabetic complications, al-
though the therapeutic target and timing of intervention
for the prevention of macroangiopathic complications have
not been well documented compared to relevant action for
the reduction of microangiopathy complications [9-11].
The need for effective glycaemic control in the early
stages of the disease has modified treatment of T2DM in
patients not adequately controlled with life style changes
and oral hypoglycaemic agents, bringing insulin into prom-
inence as an effective therapeutic intervention even in the
early stages of the disease and before secretory failure of β-
cells occurs. The combination of oral hypoglycaemic agents
and insulin administration has become a favourable type of
treatment achieving effective control with lower insulin
dosage in T2DM. The benefits of insulin administration onpreservation of β-cell secretory capacity, the antinflam-
matory action and the dose dependent hypoglycaemic
activity are combined with the favourable effects of some
OAD like metformin on insulin resistance and glucagon-
like-peptide-1 (GLP-1) agonists and dipeptyl-peptidase-4
(DPP-4) inhibitors on β-cell mass preservation and appe-
tite as well as on weight control [12,13].
The advent of insulin analogues and especially the
basal insulins have facilitated initiation of insulin treat-
ment and reduced the incidence of hypoglycaemic epi-
sodes which was a certain barrier for insulin therapy in
the early stages of T2DM [14]. The treatment guidelines
suggested by the American Diabetes Association (ADA)
and the European Association for the Study of Diabetes
(EASD) [1,2,15] and the introduction of simple instruc-
tions for insulin titration [14-18] resulted in an increase
of the use of insulin in patients with T2DM.
Table 4 Monthly number (mean ± SD) of hypoglycemic
episodes and number (%) of patients with
hypoglycaemia per treatment group during the reporting









Mild/moderate 0.757 ± 2.294 0.705 ± 1.852 0.926
Nocturnal 0.076 ± 0.466 0.053 ± 0.195 0.961
Serious 0.017 ± 0.182 0.007 ± 0.063 0.833
Table 6 Number of daily rapid-acting insulin injections,
biphasic or glargine insulin and total daily insulin dose






Number of insulin injections, n (%)
1 16 (10.1) 45 (31.7)
2 85 (53.5) 20 (14.1)
3 58 (36.5) 27 (19.0) <0.001
4 0 (0.0) 49 (34.5)
5 0 (0.0) 1 (0.7)
Mean ± SD daily units of rapid
acting insulin (U/day)
9.5 ± 2.3 23.3 ± 18.4 <0.001
Mean ± SD daily units of rapid
acting insulin (U/Kg/day)
0.12 ± 0.03 0.29 ± 0.23 <0.001
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either alone or in combination with OAD depending on
the severity of the disease and appointed glycaemic tar-
gets. It can be administered once daily as basal insulin
usually in combination with 1 or 2 OAD, basal insulin in
combination with fast acting insulin, premeal bolus short
acting insulin or in the form of a premixed intermediate
acting/fast acting combinations (biphasic) insulin [15].
In the present study we assessed the efficacy and safety
of two insulin regimens in subjects with T2DM who had
been already on treatment with biphasic human insulin
in combination with OAD, without achieving optimal
glycaemic control.
A total of 142 patients who had switched treatment
from biphasic human insulin to insulin glargine daily
were included in the active group and compared to 159
patients who continued treatment with biphasic human
insulin bd and were included in the control group. We
have shown that the reduction in HbA1c and fasting BG
values achieved were significantly greater in the active
than in the control group. In particular, HbA1c declined
by 1.13% in the active and by 0.59% in the control group
and fasting BG declined by 47 mg/dl in the active and
20 mg/dl in the control group.
It must also be emphasized that despite more inten-
sive management in the active group, the number of
hypoglycaemic episodes did not differ and body weight
did not increase in comparison with the control group.
Moreover, only one third of the patients in the active
treatment group required three injections of fast acting
insulin in addition to basal insulin glargine, the dosage
of which was considerably reduced at the end of theTable 5 Relative risk (RR) for at least one hypoglycaemic











Mild/moderate 58 (38.7) 56 (39.7) 0.98 (0.82, 1.18) 0.855
Nocturmal 20 (13.4) 18 (12.8) 1.01 (0.92, 1.10) 0.869
Serious 3 (2.0) 3 (2.1) 1.00 (0.97, 1.03) 1.0monitoring period as a consequence of the addition of
fast acting insulin.
Well controlled studies on the comparative evaluation
of the effectiveness and safety of the different insulin
schemes are limited. Raskin et al. [19] in a 28-week par-
allel group randomized study involving 233 insulin-naïve
patients with T2DM on treatment with metformin,
found that biphasic insulin twice daily was more effect-
ive in lowering HbA1c compared to treatment with once
daily insulin glargine. However, weight gain was greater
and minor hypoglycaemic episodes were more often in
the group treated with biphasic insulin. Similar results
were presented by Holman et al. [17] in an open label
one year controlled study involving 708 patients on met-
formin and sulfonylurea treatment randomized in three
insulin treatment groups, biphasic insulin twice daily,
fast acting insulin three times daily or basal insulin once
daily (or twice if required). However, their results were
modified three years after randomization and patients
who added a basal or fast acting insulin-based regimen
had better glycaemic control than patients who added
biphasic insulin [20].
Another study examined the efficacy and safety of two
treatment regimens (intensified basal-bolus glargine/
glulisine regimen and biphasic insulin twice daily) for
52 weeks in 312 patients with long-standing T2DM ini-
tially treated with biphasic insulin. The study showed
that patients allocated in the basal-bolus regimen had su-
perior glycaemic control vs. those allocated in the premix
therapy with no increase in the rates of hypoglycaemia
[21]. In addition more patients reached HbA1c ≤ 7% in
the basal-bolus than in the biphasic treatment group
(46.6% vs. 27.9%).
In a meta-analysis, Lasserson et al. [22] reviewed 22
trials that randomized 4,379 insulin-naïve patients. They
found greater HbA1c reductions with biphasic and fast
acting insulin compared with basal insulin, but at the
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phasic and fast acting arms with minor hypoglycaemic
events being inconsistently higher in biphasic and fast
acting groups and weight gain greater in the fast acting
group compared to the group on basal insulin.
In our study the addition of fast acting insulin when ne-
cessary to basal insulin glargine resulted in greater HbA1c
and fasting BG reduction, which almost reached the sug-
gested by the ADA/EASD guidelines levels [1,2,15]. This
was achieved with no increase in weight or in the rate of
hypoglycaemic episodes. The recent guidelines for the
management of T2DM suggest that not all patients need
or benefit from aggressive glucose management and that
it is important to individualize treatment targets [15]. Be-
cause most of the T2DM patients maintain some en-
dogenous insulin secretion even in late stages of disease,
addition of basal insulin [neutral protamine Hagedorn
(NPH) or long-acting insulin glargine or insulin detemir)]
to the OAD if glucose control is inadequate is an effective,
safe and simple approach, unless the patient is markedly
hyperglycemic [15]. Our results showed that almost 30%
of the participants managed to achieve glucose targets
only with insulin glargine once daily. However, almost
40% of the participants in the control and 54% of the par-
ticipants in the active group needed 3or more insulin in-
jections per day. Moreover, we found that with basal
insulin regimens, the addition of medications-beyond
metformin-that increase insulin secretion like sulfonyl-
ureas or meglitinides is necessary in some patients for the
maintenance of glycaemic control; thus, more patients in
the active group received such medications during follow-
up. Therefore, our data suggest that addition of basal insu-
lin to OAD is an effective approach for the management
of hyperglycaemia in T2DM and intensification of insulin
therapy with the addition of fast-acting pre-meal insulin
may be necessary to achieve glucose targets.
The combination of basal insulin with fast acting insulin
when needed offers greater flexibility and better glycaemic
control mimicking the physiologic insulin secretion. Due
to its pharmacodynamic profile, insulin glargine substi-
tutes basal insulin secretion effectively controlling morn-
ing glycaemia, whereas fast acting insulin reduces
postprandial hyperglycaemia.
The strength of this study is that it examined in every-
day clinical practice with no intervention at all and with
adequate power the effectiveness of intensification of
treatment with insulin based on two insulin regimens
(basal insulin glargine vs. biphasic human insulin) on gly-
cemic control. In addition, the study has adequate power
to support the findings. However, this study being obser-
vational and retrospective by design has several limita-
tions. First, the two groups differ significantly at baseline
in terms of age, BMI, known duration of diabetes and dia-
betes control. Moreover, at the end of the monitoringperiod there were significant differences in concomitant
treatments for diabetes; thus the results should be
interpreted taking into consideration the changes in medi-
cations used for the treatment of diabetes during the
study. Second, the number of mild/moderate hypoglycaemic
episodes might have been under-reported in medical records
and therefore, underestimated. Third, detailed data for
documented symptomatic hypoglycaemia, asymptom-
atic hypoglycaemia, probable symptomatic hypoglycaemia
and relative hypoglycaemia were not available and all cases
of hypoglycaemia other than severe hypoglycaemia were
classified as mild or moderate hypoglycaemia. Fourth,
causality between the treatments and the outcomes can-
not be established and these findings must be confirmed
by a randomized clinical trial.
Conclusions
Our findings suggest that treatment with basal insulin
glargine alone or in combination with fast acting insulin
is more effective in reducing glycaemia compared to
treatment with biphasic human insulin alone or in com-
bination with fast acting insulin in patients with T2DM
already on treatment with biphasic human insulin only,
without any increase in hypoglycaemic episodes or body
weight.
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